ArticleBriefings in bioinformatics2026
DADA-EV: domain-adaptive diffusion autoencoder for estimating tissue- and cell-type-specific origin in extracellular vesicle transcriptomes.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune cell-derived exosomes in cancer: double-edged mechanisms of antitumor immunity and tumor progression.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Tracing the tissue and cell-type origins of extracellular vesicles (EVs) in blood is critical for liquid biopsy and precision medicine, yet existing deconvolution methods remain limited by the need for labor-intensive reference signatures and poor adaptability to distribution shifts between tissue/cell-type datasets and EV transcriptomes. We introduce DADA-EV (Domain-Adaptive Diffusion Autoencoder for EVs), a hybrid deep learning framework that combines an autoencoder backbone with a generative simulation module and adversarial domain adaptation. DADA-EV features three key innovations: (1) a reference-free design that eliminates reliance on predefined signatures; (2) cross-domain generalization by aligning feature distributions between source (tissue/cell-type) and target (EV) domain; and (3) reduced dependence on source data during target-domain training. Extensive evaluations on pseudo-EV data show that DADA-EV consistently outperforms existing approaches, yielding accurate fraction estimates across diverse tissues and gene sets. Validation using in vitro cell-line mixtures further confirms its reliability in resolving complex compositions, demonstrating high sensitivity in detecting low-abundance targets. Applied to real EV transcriptomes, it reveals tissue- and cell-type heterogeneity across patient groups. In summary, DADA-EV provides a robust, reference-free, and generalizable solution for EV origin tracing, with strong potential to advance diagnosis, prognosis, and treatment monitoring via liquid biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.